Literature DB >> 19020747

Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.

Kazumoto Murata1, Atsushi Sakamoto.   

Abstract

Des-gamma-carboxy prothrombin (DCP) has been well established as a hepatocellular carcinoma (HCC) tumor marker. However, the precise mechanism by which HCC cells produce DCP remains unknown. Importantly, DCP is not specific for HCC. For example, vitamin K-deficiency or ingestion of a vitamin K antagonist (warfarin) also leads to DCP production. In addition, supplementary administration of vitamin K2 analogues to HCC patients has led to reduce serum DCP levels. From these observations, we hypothesize that DCP might be produced from HCC cells with functional impairment of vitamin K uptake. Because, as previously reported, the down-regulation of E-cadherin or high serum DCP in HCC patients is associated with a high risk of vascular invasion, intra-hepatic metastasis and tumor recurrence, we examined if HCC cells might produce DCP by epithelial to fibroblastoid conversion (EFC) in vitro. HepG2 cells were induced EFC by tumor promoter, 12-O-tetracanoylphorbol-13-acetate (TPA). DCP production was observed in HepG2 cells that had lost E-cadherin expression in a TPA-dose-dependent manner. The DCP production was inhibited by introducing additional vitamin K2 into the treated cells. In addition, LDL uptake as a surrogate of vitamin K uptake was significantly impaired in TPA-treated HepG2 cells. The cells with impairment of LDL uptake produced DCP. Fat soluble vitamins are taken up into cells through clathrin-mediated endocytosis, in which the dynamic polymerization of F-actin plays a crucial role. We found that HepG2 cells with F-actin rearrangement produced DCP. In addition, latrunculin A, an actin depolymerizer, induced naïve HepG2 cells to produce DCP, confirming that impairment of F-actin polymerization is a key mechanism of DCP production. We showed in vitro that cytoskeletal filament change by EFC is crucial for DCP production in HepG2 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020747

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Association of des-γ-carboxy prothrombin production and Sonazoid-enhanced ultrasound findings in hepatocellular carcinomas of different histologic grades.

Authors:  Kazumoto Murata; Akiko Saito; Satoshi Katagiri; Shunichi Ariizumi; Masayuki Nakano; Masakazu Yamamoto
Journal:  J Med Ultrason (2001)       Date:  2017-08-21       Impact factor: 1.314

2.  Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.

Authors:  Hideto Suzuki; Kazumoto Murata; Takaya Gotoh; Masao Kusano; Hiroshi Okano; Takashi Oyamada; Yoshikazu Yasuda; Masatoshi Imamura; Masatoshi Kudo; Masashi Mizokami; Atsushi Sakamoto
Journal:  J Gastroenterol       Date:  2011-07-09       Impact factor: 7.527

3.  Tropomyosin3 overexpression and a potential link to epithelial-mesenchymal transition in human hepatocellular carcinoma.

Authors:  Hye-Sun Choi; Seon-Hee Yim; Hai-Dong Xu; Seung-Hyun Jung; Seung-Hun Shin; Hae-Jin Hu; Chan-Kwon Jung; Jong Young Choi; Yeun-Jun Chung
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

4.  Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma.

Authors:  Bu-Yeo Kim; Dong Wook Choi; Seon Rang Woo; Eun-Ran Park; Je-Geun Lee; Su-Hyeon Kim; Imhoi Koo; Sun-Hoo Park; Chul Ju Han; Sang Bum Kim; Young Il Yeom; Suk-Jin Yang; Ami Yu; Jae Won Lee; Ja June Jang; Myung-Haing Cho; Won Kyung Jeon; Young Nyun Park; Kyung-Suk Suh; Kee-Ho Lee
Journal:  BMC Genomics       Date:  2015-04-10       Impact factor: 3.969

5.  Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma.

Authors:  Yoshimichi Haruna; Noriko Hasegawa; Kazuho Imanaka; Seiichi Kawamoto; Atsuo Inoue
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

6.  MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.

Authors:  Fuliang Qian; Jinghan Wang; Ying Wang; Qian Gao; Wenying Yan; Yuxin Lin; Li Shen; Yufeng Xie; Xiaoqing Jiang; Bairong Shen
Journal:  Clin Transl Med       Date:  2021-02

7.  Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study.

Authors:  Yoshimichi Haruna; Takayuki Yakushijin; Seiichi Kawamoto
Journal:  Cancer Med       Date:  2021-01-22       Impact factor: 4.452

8.  Transgelin: a new gene involved in LDL endocytosis identified by a genome-wide CRISPR-Cas9 screen.

Authors:  Diego Lucero; Ozan Dikilitas; Michael M Mendelson; Zahra Aligabi; Promotto Islam; Edward B Neufeld; Aruna T Bansal; Lita A Freeman; Boris Vaisman; Jingrong Tang; Christian A Combs; Yuesheng Li; Szilard Voros; Iftikhar J Kullo; Alan T Remaley
Journal:  J Lipid Res       Date:  2021-12-10       Impact factor: 5.922

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.